Alterations in plasma L-arginine and methylarginines in heart failure and after heart transplantation
暂无分享,去创建一个
[1] G. Rådegran,et al. Plasma l-arginine levels distinguish pulmonary arterial hypertension from left ventricular systolic dysfunction , 2017, Heart and Vessels.
[2] G. Rådegran,et al. Impact of postoperative pulmonary hypertension on outcome after heart transplantation , 2017, Scandinavian cardiovascular journal : SCJ.
[3] R. Wachter,et al. Left ventricular heart failure and pulmonary hypertension , 2015, European heart journal.
[4] Sanjiv J. Shah,et al. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. , 2015, JAMA.
[5] G. Wikström,et al. Changes in plasma levels of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine after a single dose of vardenafil in patients with pulmonary hypertension. , 2015, Vascular pharmacology.
[6] G. Rådegran,et al. Hemodynamic Characteristics Including Pulmonary Hypertension at Rest and During Exercise Before and After Heart Transplantation , 2015, Journal of the American Heart Association.
[7] C. Jung,et al. Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? , 2013, Cardiovascular research.
[8] S. Hazen,et al. Diminished global arginine bioavailability as a metabolic defect in chronic systolic heart failure. , 2013, Journal of cardiac failure.
[9] H. Figulla,et al. Increased arginase levels in heart failure represent a therapeutic target to rescue microvascular perfusion. , 2013, Clinical hemorheology and microcirculation.
[10] N. Frey,et al. The L-Arginine-asymmetric dimethylarginine ratio is an independent predictor of mortality in dilated cardiomyopathy. , 2012, Journal of cardiac failure.
[11] Shing‐Jong Lin,et al. Asymmetric dimethylarginine predicts clinical outcomes in ischemic chronic heart failure. , 2012, Atherosclerosis.
[12] A. Melidonis,et al. Plasma asymmetric dimethylarginine and mortality in patients with acute decompensation of chronic heart failure , 2012, Heart.
[13] James D. Thomas,et al. Pulmonary hypertension associated with advanced systolic heart failure: dysregulated arginine metabolism and importance of compensatory dimethylarginine dimethylaminohydrolase-1. , 2012, Journal of the American College of Cardiology.
[14] V. Roger,et al. Pulmonary pressures and death in heart failure: a community study. , 2012, Journal of the American College of Cardiology.
[15] H. Arnesen,et al. The L-arginine-asymmetric dimethylarginine ratio is strongly related to the severity of chronic heart failure. No effects of exercise training. , 2011, Journal of cardiac failure.
[16] W. Paulus,et al. The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature , 2010, European journal of heart failure.
[17] E. Benjamin,et al. Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community , 2009, Circulation.
[18] H. Valantine,et al. Asymmetric Dimethylarginine and Cardiac Allograft Vasculopathy Progression: Modulation by Sirolimus , 2008, Transplantation.
[19] Maristela L Onozato,et al. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. , 2007, American journal of physiology. Heart and circulatory physiology.
[20] W. Durante,et al. ARGINASE: A CRITICAL REGULATOR OF NITRIC OXIDE SYNTHESIS AND VASCULAR FUNCTION , 2007, Clinical and experimental pharmacology & physiology.
[21] D. Kass,et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. , 2006, JAMA.
[22] Silviu Itescu,et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[23] R. Böger. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. , 2004, The Journal of nutrition.
[24] J. Kjekshus,et al. Hypertension in relation to nitric oxide, asymmetric dimethylarginine, and inflammation: different patterns in heart transplant recipients and individuals with essential hypertension , 2002, Transplantation.
[25] Shing‐Jong Lin,et al. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. , 2002, The American journal of cardiology.
[26] A. Selwyn,et al. The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. , 1998, The American journal of cardiology.
[27] T. Imaizumi,et al. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. , 1998, Life sciences.
[28] T. Rector,et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. , 1996, Circulation.
[29] J. Cooke,et al. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. , 1992, The Journal of clinical investigation.
[30] S. Moncada,et al. Vascular endothelial cells synthesize nitric oxide from L-arginine , 1988, Nature.